HHS and VA launch a federal partnership to study psychedelic therapies for veterans, focusing on PTSD, depression, substance use and suicide prevention

HHS and the U.S. Department of Veterans Affairs are forming a federal partnership to advance research on psychedelic therapies for veterans with serious mental health needs. The effort centers on conditions that heavily affect veterans, including PTSD, depression, substance use disorders, and suicide risk. The collaboration is intended to speed scientific evaluation, improve coordination across agencies, and identify therapeutic approaches that could become safe and effective treatment options. Veterans' care needs and the lack of sufficient responses to existing treatments make psychedelic medicine a growing priority in federal health policy. The announcement signals mainstream government interest in psychedelics as a research and treatment frontier. It also frames psychedelic therapy less as counterculture and more as a potential evidence-based tool within regulated clinical care for veteran populations.